Nkarta 3Q 2026: EPS ($0.45) — 10-Q Summary

Nkarta reported a wider net loss in 3Q 2026, with a loss of $33.33M compared to $21.72M a year earlier, due to increased R&D spending and lower interest income. R&D expenses rose to $29.5M, driven by higher program costs and clinical spending for NKX019. The company had $216.0M in cash and investments as of September 30, 2026, and is conducting clinical trials for NKX019 in various conditions.

Original reporting
Published Nov 5, 2026, 9:41 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 5, 2026, 9:49 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Nkarta 3Q 2026: EPS ($0.45) — 10-Q Summary — source image
Decision brief

The 30-second read

$NKTXBearishLow
01

Why it matters

The widened loss highlights higher cash burn, likely pressuring the stock in the near term.

02

Market read

First disclosure of Q3 2026 results; investors will reassess valuation based on loss magnitude and cash runway.

03

What to watch

Potential upcoming clinical data for NKX019 may offset short‑term loss concerns.

Relevance 6/10Novelty 7/10Timing: post‑market release today

Background

Nkarta's 10‑Q provides detailed financials and updates on its NKX019 program.

Company-level read

Ticker impact

$NKTXBearishHigh confidence
Context

Nkarta filed its 10‑Q showing a widened net loss of $33.33M and EPS of -$0.45 for Q3 2026.

Expected impact

downward pressure as investors price in higher R&D spend and larger loss.

Evidence & confidence

First‑time disclosure of a material loss increase; market typically reacts negatively to widening losses.

Market effects

Biotech sector may see broader risk‑off sentiment due to higher R&D burn rates.

U.S. small‑cap biotech investors may adjust exposure.

Limited to investors tracking U.S. biotech earnings.

Counterpoint

The cash runway of $216M could support future milestones, offering a buying opportunity at depressed prices.

Key entities

  • Nkarta, Inc.

    U.S. biotech firm developing NKX019.

Related articles

$NKTXHighAI 8/10

Nkarta reports safety data for autoimmune cell therapy NKX019

Nkarta Inc. (NKTX) presented safety data for NKX019, its CD19-directed CAR NK cell therapy, in a clinical trial for autoimmune diseases. The data, from 40 patients, showed no serious adverse events. Treatment-emergent adverse events occurred in 85% of patients, with 35% experiencing grade 3 or higher events, primarily hematologic. NKX019 is manufactured from donor-derived NK cells.

$NKTXMedAI 8/10

Nkarta Reports Initial NKX019 Clinical Responses in Myositis and Systemic Sclerosis Trials

Nkarta (NKTX) presented early clinical data for NKX019, showing positive responses in myositis and systemic sclerosis trials. 83% of myositis patients and 86% of systemic sclerosis patients responded to treatment. Safety data from 40 patients showed no serious adverse events. Nkarta plans to evaluate a higher dose and engage with the FDA for potential registration pathways.

$NKTXMedAI 9/10

Nkarta reports early trial data for autoimmune cell therapy

Nkarta Inc. (NKTX) presented early trial data for NKX019, an experimental cell therapy for autoimmune diseases. In trials with 40 patients, 83% of myositis patients and 86% of systemic sclerosis patients showed significant responses. No serious adverse events were reported. Nkarta plans to evaluate higher doses and discuss potential registration pathways with the FDA.

$NKTXLow

Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026

Nkarta, Inc. (NKTX) filed an SEC Form 8-K — Regulation FD Disclosure. Exhibit 99.1 Nkarta to Host Webcast to Discuss Initial Clinical Data for NKX019 in Autoimmune Diseases at ACR Convergence 2026 SOUTH SAN FRANCISCO, Calif., November 6, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biotechnology company developing engineer